Searched for
EISAI INC.
Glenmark launches generic cancer treatment drug in USGlenmark Pharmaceuticals on Tuesday launched Eribulin Mesylate Injection, a generic cancer treatment, in the US through its subsidiary Glen...- Japan's Nikkei closes at 2-week high on tech boostJapan's central bank last month widened the trading band for the benchmark 10-year government bonds to 0.5% from 0.25%, sending yields acro...
- New Alzheimer drug 'lecanemab' by Eisai Co and Biogen shows positive results but......, read what study saysThe ‘Eisai’ and ‘Biogen’ drug slowed cognitive decline in study participants, but many experienced brain bleeds, swelling, or other side ef...
- Japan's Topix hits highest since 1990 on hopes of new govt, better earningsThe Nikkei average rose 1.25 per cent to 30,381.84, the ninth session of gains in the last ten. For the week, it was up 4.3 per cent.
- Nikkei climbs 1% at close; Japan shares track Nasdaq higher, drug makers shineThe Nikkei jumped 0.96 per cent to 29,441.30, posting its biggest gain since late May, while the broader Topix rose 0.8 per cent to 1,975.4...
- Nikkei closes flat; Japan shares end lower as cyclical stocks dragThe Nikkei share average closed 0.03 per cent down at 28,948.73, while the broader Topix slipped 0.14 per cent to 1,954.02. For the week, t...
- Heavyweights pull Nikkei lower, Topix gains on drugmakers' boostNikkei inched down 0.2 per cent to close at 28,963.56, while the Topix edged up 0.1 per cent at 1,962.65.
- Glenmark Pharma launches anti-epileptic drug, Rufinamide, in the USThe newly launched drug is a therapeutic equivalent of Banzel tablets, 200 mg and 400 mg of Eisai, Inc. Banzel tablets are used in combinat...
- Japanese shares gain tracking US futures; tech and pharma stocks boostThe Nikkei share average gained 0.67 per cent at 28.822.29, after declining 0.2 per cent earlier, while the broader Topix inched up 0.29 pe...
- Nikkei hits over 2-year high on Wall Street boost, focus on final US election tallyAnalysts said stocks were supported by overnight Wall Street gains as the likelihood of gridlock in Congress made investors optimistic that...
- Japan shares hit 5-week high on vaccine, economic growth hopesThe Nikkei index settled 1.59% higher at 22,945.50 after hitting its highest level since June 10, with industrial and consumer discretional...
- Japanese shares snap 3-day losing streak as battered stocks bought backThe Nikkei share average rose 1.52 per cent to 19,429.44 after three straight sessions of losses.
- Nikkei falls steepest in 3 months as growth slowdown bitesThe Nikkei share average stumbled 3 per cent to 20,977.11, the lowest since mid-February.
- Nikkei closes flat even as chip makers make a buzzChip equipment makers jumped, tracking a rise in US tech shares overnight.
- Lupin launches generic Aricept tablets in US marketLupin's product is a generic version of Eisai Inc's Aricept tablets which is indicated for the treatment of dementia of the Alzheimer's typ...
- Lupin gets FDA nod for generic Aricept tabletsLupin said it has received final approval from the US drug regulator to market generic Aricept tablets used for treatment of dementia.
- Helsinn Healthcare in settlement agreement with Dr Reddy'sAccording to a statement by the drug maker, Aloxi is currently distributed by Helsinn Healthcare's marketing partner, Eisai Inc in the USA.
- Lupin launches generic GERD drug in the US marketUsed to treat gastroesophageal reflux disease.
- Indian companies in FDA's first list for generic Aciphex tabletsIndian firms including Dr Reddy's, Lupin and Torrent Pharma have received nod from the US health regulator to market the first generic vers...
- Dr Reddy's launches Alzheimer's disease drug in US marketDr Reddy's Laboratories today said it has launched generic Donepezil Hydrochloride tablets, used to treat Alzheimer's disease, in the US ma...
Load More
